Northwest Biotherapeutics (NWBO) Operating Expenses (2010 - 2026)

Northwest Biotherapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $11.4 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 35.58% year-over-year to $11.4 million; the TTM figure through Mar 2026 stood at $55.0 million (down 20.92% YoY), while the FY2025 annual figure was $61.3 million, down 9.72% from the prior year.
• Operating Expenses for Q1 2026 stood at $11.4 million, down from $14.2 million in the prior quarter.
• The five-year high for Operating Expenses was $21.6 million in Q2 2022, with the low at $11.4 million in Q1 2026.
• The 5-year median for Operating Expenses is $15.2 million (2024), against an average of $15.7 million.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 75.86% in 2022, then sank 36.14% in 2023.
• Northwest Biotherapeutics' Operating Expenses stood at $18.8 million in 2022, then slipped by 16.98% to $15.6 million in 2023, then increased by 20.16% to $18.7 million in 2024, then dropped by 24.31% to $14.2 million in 2025, then declined by 19.62% to $11.4 million in 2026.
• Business Quant data shows NWBO's Operating Expenses at $11.4 million in Q1 2026, $14.2 million in Q4 2025, and $14.5 million in Q3 2025.